Interests:Health economics, access to medicines, market dynamics and product development, public-private partnerships.
Skills:Strategy development, economic analysis, and evaluation.
Background and relevant experience:Cheri is a global health professional with 25 years of experience in a variety of work settings - pharmaceutical industry; corporate finance; grassroots development; academic research, and global health management consulting - specialising in market dynamics and R&D incentives for health products. Her work in market dynamics began in 2001, before the term market dynamics came into common usage, with an assignment for WHO’s Essential Drugs and Medicines Policy Department on differential pricing. She has since worked across different disease areas, technology types (medicines, diagnostics, LLINs, vaccines) and also including different stages of the technology life cycle, from early stage R&D through to mature, generic products. Cheri’s work also includes issues related to technology introduction and access to medicines at an international as well as country level. She has worked in over 20 aid recipient countries for more than 1 month and an even wider range of countries through working in 3 consecutive DFID Health Resource Centres over a period of 8 years. This work has encompassed (for example) aid effectiveness, health systems strengthening, capacity development, gender and equity, fragile states, and private versus public strategies for health service provision.
- UNITAID: Proposal Review Committee (PRC) Market Dynamics Expert
- Global Fund to Fight AIDS, TB and Malaria: Technical Review Panel
- Global Alliance for TB Drug Development (TB Alliance): Access Advisory Committee
- World Health Organisation: Expert Reviewer on a series of local pharmaceutical production studies.
Selected examples of recent and current projects
- Technical Lead: Evaluation of £35 million grant to Clinton Health Access Initiative (UK DFID)
- Evaluation of the Disease Control Priority Network (Bill and Melinda Gates Foundation)
- Team leader: Review of supply side issues of anti-malaria medicines and technologies, for the Access to Quality Medicine and Other Technology Task Force
- Evaluation of the Quality Reproductive Health Medicines Programme (UK DFID and the Bill and Melinda Gates Foundation)
- Mid-term review of £50 million ICOSA schistosomiasis programme (UK DFID)
- Value for Money support to the International AIDS Vaccine Initiative (IAVI)
- Business case for £300 million support to polio eradication (UK DFID)
- Business case for £50 million support to neglected tropical disease control (UK DFID)
- Team leader: Strategy development – neglected disease product R&D opportunities for investment (Australian Department of Foreign Affairs and Trade)
- Evaluation of GAVI’s Innovative Financing Facility for Immunization – vaccine market impact focus (The Vaccine Alliance)
- Team leader: Evaluation of pooled funding proposals to accelerate R&D funding for neglected diseases (The Bill and Melinda Gates Foundation)
- Team leader: Independent evaluation of 8 Product Development Public-Private Partnerships: (The Netherlands Ministry of Foreign Affairs)
Selected examples of employment prior to 2011
- Lead Specialist Access to Medicines, HLSP 2006 – 2011
- Senior Health Advisor: UK Department for International Development: Developed DFID’s work through Product Development Public-Private Partnerships, and supported work in Advance Market Commitments and the broader Access to Medicines agenda. 2005- 2006
- Health Systems Specialist, DFID Health Resource Centre 2003 – 2005
- Research Associate at the DFID-funded Development Research Centre at London Business School 1999-2003
For Education and Publications, see:http://www.linkedin.com/pub/cheri-grace/11/949/641
For an up to date CV email Cheri at the address at the top of this profile.